Therapeutic effects of dasatinib in mouse model of multiple sclerosis

Immunopharmacology and Immunotoxicology

Volumn 37, Issue 3, 2015, Pages 287-294

  Azizi, Gholamreza ^a,b   Goudarzvand, Mahdi ^a   Afraei, Sanaz ^c   Sedaghat, Reza ^d   Mirshafiey, Abbas ^e  

^a ALBORZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF TEHRAN   (Iran)

^d SHAHED UNIVERSITY   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Dasatinib; Experimental autoimmune encephalomyelitis; Matrix metalloproteinase 2; Multiple sclerosis; Nitric oxide

Indexed keywords

DASATINIB; FREUND ADJUVANT; GELATINASE A; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA; MMP2 PROTEIN, MOUSE; MYELIN OLIGODENDROCYTE GLYCOPROTEIN (35-55); PEPTIDE FRAGMENT; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; ASTROCYTOMA CELL LINE; BLOOD LEVEL; BLOOD SAMPLING; BRAIN CORTEX; CELL PROLIFERATION; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; EMULSION; ENZYME ACTIVITY; ENZYME INHIBITION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; GRAY MATTER; HIPPOCAMPUS; HISTOPATHOLOGY; IMMUNIZATION; IMMUNOMODULATION; IN VITRO STUDY; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; ONSET AGE; PRIORITY JOURNAL; THERAPY EFFECT; WHITE MATTER; ANIMAL; CHEMICALLY INDUCED; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; IMMUNOLOGY; PATHOLOGY; TUMOR CELL LINE;

MUS;

ANIMALS; CELL LINE, TUMOR; DASATINIB; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; MATRIX METALLOPROTEINASE 2; MICE; MULTIPLE SCLEROSIS; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; NITRIC OXIDE; PEPTIDE FRAGMENTS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84931061779     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.3109/08923973.2015.1028074     Document Type: Article

References (45)

1. Love S. Demyelinating diseases. J Clin Pathol. 2006; 59: 1151-1159
2. Vanheel A, Daniels R, Plaisance S, et al. Identification of protein networks involved in the disease course of experimental autoimmune encephalomyelitis: an animal model of multiple sclerosis. PLoS One. 2012; 7: e35544
3. Koguchi Y, Buenafe AC, Thauland TJ, et al. Preformed CD40L is stored in Th1, Th2, Th17, and T follicular helper cells as well as CD4+ 8-Thymocytes and invariant NKT cells but not in Treg cells. PLoS One. 2012; 7: e31296
4. Sulavik MC, Tardif G, Clewell DB. Identification of a gene, rgg, which regulates expression of glucosyltransferase and influences the SPP phenotype of Streptococcus gordonii Challis. J Bacteriol. 1992; 174: 3577-3586
5. Benesova Y, Vasku A, Novotna H, et al. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis. Mult Scler. 2009; 15: 316-322
6. Taupin V, Renno T, Bourbonniere L, et al. Increased severity of experimental autoimmune encephalomyelitis, chronic macrophage/.microglial reactivity, and demyelination in transgenic mice producing tumor necrosis factor-Alpha in the central nervous system. Eur J Immunol. 1997; 27: 905-913
7. Murphy AC, Lalor SJ, Lynch MA, Mills KH. Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. Brain Behav Immun. 2010; 24: 641-651
8. Miller E, Wachowicz B, Majsterek I. Advances in antioxidative therapy of multiple sclerosis. Curr Med Chem. 2013; 20: 4720-4730
9. Zaheer S, Wu Y, Bassett J, et al. Glia maturation factor regulation of STAT expression: a novel mechanism in experimental autoimmune encephalomyelitis. Neurochem Res. 2007; 32: 2123-2131
10. Lee DH, Gold R, Linker RA. Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: therapeutic modulation via fumaric acid esters. Int J Mol Sci. 2012; 13: 11783-11803
11. Zindler E, Zipp F. Neuronal injury in chronic CNS inflammation. Best Pract Res Clin Anaesthesiol. 2010; 24: 551-562
12. Smith KJ, Lassmann H. The role of nitric oxide in multiple sclerosis. Lancet Neurol. 2002; 1: 232-241
13. Moriya M, Nakatsuji Y, Miyamoto K, et al. Edaravone, a free radical scavenger, ameliorates experimental autoimmune encephalomyelitis. Neurosci Lett. 2008; 440: 323-326
14. Mirshafiey A, Ghalamfarsa G, Asghari B, Azizi G. Receptor tyrosine kinase and tyrosine kinase inhibitors: new hope for success in multiple sclerosis therapy. Innov Clin Neurosci. 2014; 11: 23-36
15. Dos Santos C, McDonald T, Ho YW, et al. The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents. Blood. 2013; 122: 1900-1913
16. Fujita H, Kitawaki T, Sato T, et al. The tyrosine kinase inhibitor dasatinib suppresses cytokine production by plasmacytoid dendritic cells by targeting endosomal transport of CpG DNA. Eur J Immunol. 2013; 43: 93-103
17. Brownlow N, Mol C, Hayford C, et al. Dasatinib is a potent inhibitor of tumour-Associated macrophages, osteoclasts and the FMS receptor. Leukemia. 2009; 23: 590-594
18. Schieven GL, Zhang R, Pitt S, et al. Dasatinib potential for antiinflammatory efficacy while avoiding suppression of T cell activation in preclinical models. J Immunol. 2009; 182: 33-38
19. Porkka K, Koskenvesa P, Lundan T, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood. 2008; 112: 1005-1012
20. Schade AE, Schieven GL, Townsend R, et al. Dasatinib, a smallmolecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood. 2008; 111: 1366-1377
21. Futosi K, Németh T, Pick R, et al. Dasatinib inhibits proinflammatory functions of mature human neutrophils. Blood. 2012; 21: 4981-4991
22. Das J, Chen P, Norris D, et al. 2-Aminothiazole as a novel kinase inhibitor template. Structure-Activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-Thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J Med Chem. 2006; 49: 6819-6832
23. Zhang RL, Chopp M, Chen H, Garcia JH. Temporal profile of ischemic tissue damage, neutrophil response, and vascular plugging following permanent and transient (2H) middle cerebral artery occlusion in the rat. J Neurol Sci. 1994; 125: 3-10
24. Jacobs MA, Zhang ZG, Knight RA, et al A model for multiparametric mri tissue characterization in experimental cerebral ischemia with histological validation in rat: Part 1. Stroke: J Cereb Circul. 2001; 32: 943-949
25. Grisham MB, Johnson GG, Lancaster Jr JR. Quantitation of nitrate and nitrite in extracellular fluids. Methods Enzymol. 1996; 268: 237-246
26. Mosayebi G, Haghmorad D, Namaki S, et al. Therapeutic effect of EDTA in experimental model of multiple sclerosis. Immunopharmacol Immunotoxicol. 2010; 32: 321-326
27. Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of ''antioxidant power'': the FRAP assay. Anal Biochem. 1996; 239: 70-76
28. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65: 55-63
29. Azizi G, Haidari MR, Khorramizadeh M, et al. Effects of imatinib mesylate in mouse models of multiple sclerosis and in vitro determinants. Iran J Allergy Asthma Immunol. 2014; 13: 198-206
30. Lopez-Diego RS, Weiner HL. Novel therapeutic strategies for multiple sclerosis - A multifaceted adversary. Nat Rev Drug Discov. 2008; 7: 909-925
31. Mirshafiey A, Ghalamfarsa G, Asghari B, Azizi G. Receptor tyrosine kinase and tyrosine kinase inhibitors: new hope for success in MS therapy. Innov Clin Neurosci. 2014; 11: 23-36
32. Azizi G, Mirshafiey A. Imatinib mesylate: an innovation in treatment of autoimmune diseases. Recent Pat Inflamm Allergy Drug Discov. 2013; 7: 259-267
33. Fraser CK, Lousberg EL, Kumar R, et al. Dasatinib inhibits the secretion of TNF-Alpha following TLR stimulation in vitro and in vivo. Exp Hematol. 2009; 37: 1435-1444
34. Blaise GA, Gauvin D, Gangal M, Authier S. Nitric oxide, cell signaling and cell death. Toxicology. 2005; 208: 177-192
35. Murphy S. Production of nitric oxide by glial cells: regulation and potential roles in the CNS. Glia. 2000; 29: 1-13
36. Fereidoni M, Sabouni F, Moghimi A, Hosseini S. The effects of trypsin on rat brain astrocyte activation. Iran J Neurol. 2013; 12: 129-135
37. Echeverria V, Burgess S, Gamble-George J, et al. Sorafenib inhibits nuclear factor kappa B, decreases inducible nitric oxide synthase and cyclooxygenase-2 expression, and restores working memory in APPswe mice. Neuroscience. 2009; 162: 1220-1231
38. Fei F, Yu Y, Schmitt A, et al. Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens. Exp Hematol. 2008; 36: 1297-1308
39. Cui W, Zhang ZJ, Hu SQ, et al. Sunitinib produces neuroprotective effect via inhibiting nitric oxide overproduction. CNS Neurosci Ther. 2014; 20: 244-252
40. Ghalaut VS, Sangwan L, Dahiya K, et al. Effect of imatinib therapy with and without turmeric powder on nitric oxide levels in chronic myeloid leukemia. J Oncol Pharm Pract. 2012; 18: 186-190
41. Fonseca SG, Romao PR, Figueiredo F, et al. TNF-Alpha mediates the induction of nitric oxide synthase in macrophages but not in neutrophils in experimental cutaneous leishmaniasis. Eur J Immunol. 2003; 33: 2297-2306
42. Shiryaev SA, Savinov AY, Cieplak P, et al. Matrix metalloproteinase proteolysis of the myelin basic protein isoforms is a source of immunogenic peptides in autoimmune multiple sclerosis. PLoS One. 2009; 4: e4952
43. Buettner R, Mesa T, Vultur A, et al. Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells. Mol Cancer Res. 2008; 6: 1766-1774
44. Dhawan G, Floden AM, Combs CK. Amyloid-beta oligomers stimulate microglia through a tyrosine kinase dependent mechanism. Neurobiol Aging. 2012; 33: 2247-2261
45. Lindauer M, Hochhaus A. Dasatinib. Recent results in cancer research Fortschritte der Krebsforschung. Prog Cancer Res. 2014; 201: 27-65